drugset / Trial / NCT07035457

A Study in Healthy Men to Compare the Amount of Vicadrostat and Empagliflozin in the Blood When Taken Separately and Together

NCT07035457

Phase 1 Completed 15 enrolled Boehringer Ingelheim
RandomizedCrossoverOpen-labelTreatment

Summary

The main objective of this trial is to investigate the relative bioavailability of vicadrostat and empagliflozin when administered in combination or individually.

Timeline

Start
2025-07-02
Primary completion
2025-08-07
Completion
2025-08-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Empagliflozin Small molecule
Subject Vicadrostat Small molecule

Indications

No indication recorded.